Cargando…
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
BACKGROUND: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO. METHODS: Two...
Autores principales: | Xu, Xianglai, Zhang, Sihong, Wang, Ying, Zhu, Yanjun, Wang, Jiajun, Guo, Jianming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225196/ https://www.ncbi.nlm.nih.gov/pubmed/37031459 http://dx.doi.org/10.1002/cam4.5787 |
Ejemplares similares
-
Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression
por: Xu, Xianglai, et al.
Publicado: (2023) -
Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients
por: Xu, Xianglai, et al.
Publicado: (2023) -
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics
por: Xu, Xianglai, et al.
Publicado: (2021) -
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020) -
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)